ALKERMES, INC. for ALKERMES, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Ensure regulatory certainty for clinical trials and subsequent scheduling of FDA-approved medicines deemed to be controlled substances. HR 639/S 481, Improving Regulatory Transparency Act for New Medical Therapies Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Health Issues HCR
Confronting the opioid and mental illness epidemic HR 2872, Opioid Addiction and Modernization Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Medicare/Medicaid MMM
Maintain the program's six protected classes with respect to depression and schizophrenia S. 648, Medicare Formulary Improvement Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
Alcohol and Drug Abuse ALC
Advance the use of FDA-approved medicines to treat addiction in criminal justice and public health settings S. 524/HR 954 Comprehensive Addiction and Recovery Act S. 1695/HR 3420 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016 Senate bill/HR 2578, Commerce, Justice, Science and Related Agencies Appropriations Act of 2016 (Bureau of Prisons medication pilot, inclusion of medications in Byrne Jag)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROBERT FORMAN | — |
| PETER NORMAN | — |
| DAVID TREWOLLA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.